An independent clinical assessment of Twenty-Eight Health's telehealth reproductive care platform, including who benefits most, cost analysis, prescribing scope, and how it compares to alternatives.
An evidence-based comparison of Viome alternatives for gut microbiome testing, personalized nutrition, clinical diagnostics, and supplement recommendations, with cited research and pricing.
An independent clinical review of Viome's microbiome testing, supplement subscription, and intake process. We examine the science, cost, and alternatives with cited evidence.
An independent assessment of Viome's regulatory status, clinical evidence, safety profile, and compliance posture for its microbiome testing and personalized supplement products.
An independent, evidence-based comparison of WeightWatchers and its top alternatives for weight loss, GLP-1 access, behavioral coaching, and cost savings in 2026.
An independent clinical review of the WeightWatchers (WW) prescription and intake process after its Sequence acquisition, covering GLP-1 access, cost, telehealth workflow, and how it compares to alternatives.
An independent clinical review of Willow's prescription and intake process for GLP-1 weight-loss medications, including how consultations work, what gets prescribed, costs, and how Willow compares to alternatives.
Independent review of Winona's prescription and intake process for menopause hormone therapy, including cost, what they prescribe, legitimacy, and how it compares to alternatives.
An evidence-based comparison of Wisp and its top telehealth alternatives for UTIs, bacterial vaginosis, yeast infections, herpes treatment, and birth control.
Is Wisp legit? Yes. Prescriptions come from state-licensed MDs and NPs. It's cash-pay only, no insurance accepted, and review usually takes 2 to 12 hours.
A clinical comparison of Women's International Pharmacy alternatives for compounded BHRT, including specialized compounding pharmacies, FDA-approved options, and telehealth platforms.
An independent assessment of Women's International Pharmacy's regulatory status, compounding oversight, USP compliance, and how its safety profile compares to FDA-approved BHRT alternatives.
An independent, evidence-based breakdown of ZOE's intake process, at-home testing, CGM component, cost, and whether the personalized nutrition program is backed by real clinical data.
An independent, evidence-based analysis of ZOE personalized nutrition outcomes, CGM data, PREDICT trial results, and real user experiences. Not sponsored by ZOE.
Independent analysis of ZOE's safety record, regulatory standing, clinical evidence, and compliance posture for its personalized nutrition and CGM program.
Evidence-based dosing guide for Vyleesi (bremelanotide) in adult women ages 30-49 with HSDD. Covers the FDA-approved 1.75 mg subcutaneous dose, injection timing, frequency limits, and clinical trial data from RECONNECT.
Evidence-based monitoring guide for bremelanotide (Vyleesi) in premenopausal women aged 30 to 49 with HSDD. Covers blood pressure checks, nausea management, injection-site reactions, melanocyte screening, and follow-up timelines.
A clinician-grade review of every known and theoretical drug-drug interaction with bremelanotide (Vyleesi), including oral bioavailability effects, cardiovascular overlaps, and melanocortin pathway crosstalk.
Evidence-based guide to bremelanotide (Vyleesi) dosing adjustments for patients with hepatic impairment, including pharmacokinetic data, FDA labeling, and clinical recommendations.
Evidence-based guidance on Vyleesi (bremelanotide) missed-dose scenarios, including timing windows, dose adjustments, and when to contact your prescriber. prepared by the HealthRX.com Editorial Team.
A guide to bremelanotide (Vyleesi) safety for adults aged 50 to 64, covering cardiovascular risk, nausea, blood pressure changes, polypharmacy, and perimenopause considerations.
Clinical guidance on bremelanotide (Vyleesi) overdose management, symptoms of accidental excess dosing, expected adverse effects, and when to seek emergency care.
When do Vyleesi patents expire? A clinical breakdown of bremelanotide patent coverage, Hatch-Waxman exclusivity, and the realistic timeline for a generic or biosimilar alternative.
A clinical review of bremelanotide (Vyleesi) real-world evidence from registries, post-market surveillance, and observational studies for HSDD in premenopausal women.
Evidence-based protocols for switching between Vyleesi (bremelanotide) and flibanserin (Addyi), off-label testosterone, or other HSDD treatments, including washout timing, efficacy expectations, and safety considerations.
Find out whether Humana covers Eliquis (apixaban), which plan tiers apply, what you can expect to pay, and how generic apixaban and patient assistance programs can reduce your out-of-pocket costs.
Long-term Eliquis safety depends on why it was prescribed, the right dose, bleeding history, kidney and liver changes, and interacting medicines.
Inclisiran (Leqvio) costs about $3,250 per injection, roughly $6,500 per year. Covered under Medicare Part B, with co-pay assistance available for eligible patients.
Learn what a good apolipoprotein B (ApoB) level is, why it matters more than standard cholesterol panels, and how to lower it with lifestyle changes, statins, and other therapies.
Evidence-based tadalafil dosing guide for adults aged 30 to 49, covering on-demand and daily regimens for erectile dysfunction and BPH, with trial data, dose adjustments, and clinical considerations.
Evidence-based safety profile of tadalafil (Cialis) in adults aged 30 to 49, covering side effects, cardiovascular risk, drug interactions, daily vs. on-demand dosing, and clinical monitoring.
Evidence-based review of tadalafil safety in geriatric patients, covering dose adjustments, drug interactions, fall risk, renal considerations, and deprescribing strategies for men over 65.
A clinical history of tadalafil from early PDE5 research through FDA approval, mechanism of action, key trials, and the evolution of daily dosing for ED and BPH.
State Medicaid coverage for Cialis (tadalafil) varies widely. Learn which states cover it, prior authorization requirements, step therapy rules, appeal processes, and how to access affordable tadalafil through Medicaid.
Evidence-based safety guide for tadalafil (Cialis) in adults aged 50 to 64, covering cardiovascular risk, drug interactions, dosing adjustments, and monitoring recommendations.
Tadalafil (Cialis) is taken by mouth, not by injection. Learn how tadalafil works as an oral PDE5 inhibitor, when penile self-injection therapy applies instead, and how these two ED treatment pathways compare.
How to store Cialis (tadalafil) correctly, what affects tablet stability, and when expired tadalafil loses potency. FDA data, ICH guidelines, and pharmacokinetic evidence reviewed.
Evidence-based CJC-1295 (modified GRF 1-29) dosing guide for adults aged 30 to 49. Covers DAC and no-DAC variants, subcutaneous injection protocols, IGF-1 monitoring, and safety considerations.
Complete monitoring guide for CJC-1295 modified GRF in adults aged 30 to 49. Covers baseline labs, IGF-1 tracking, glucose surveillance, and when to adjust or stop therapy.
Evidence-based safety profile of CJC-1295 (modified GRF 1-29) for adults aged 30 to 49, including adverse effects, contraindications, monitoring protocols, and clinical trial data.
A clinical review of CJC-1295 (modified GRF 1-29) off-label applications including body composition, sleep quality, injury recovery, and anti-aging, graded by available evidence from human trials and preclinical data.
CJC-1295 modified GRF is not FDA-approved. Learn the regulatory status of CJC-1295 across the US, EU, Canada, and the UK, including 503A compounding rules, WADA bans, and clinical trial evidence.
A clinician-focused guide to choosing among biguanide formulations, covering metformin IR vs ER, brand-specific ER differences, dose titration by indication, renal adjustments, and off-label applications in PCOS and longevity.
A prescriber-level guide to billing, coding, prior authorization, and regulatory compliance for BPC-157 and TB-500 healing peptides, including compounding pharmacy workflows and cash-pay models.
Evidence-based monitoring protocol for BPC-157 and TB-500 peptide therapy. Lab panels, timing, safety signals, and clinical decision points for prescribers managing tissue-repair peptides.
A prescriber-level playbook for billing, coding, and navigating prior authorization for rapid-acting insulin analogs including lispro, aspart, and glulisine.
Evidence-based monitoring protocols for rapid-acting insulin analogs including lispro, aspart, and glulisine. Covers baseline labs, glycemic targets, hypoglycemia surveillance, and injection-site assessment for prescribers and pharmacists.
Find out if Molina Healthcare covers Vyvanse (lisdexamfetamine) for ADHD and binge eating disorder, including prior authorization requirements, step therapy, and how to verify your specific plan's rules.
A clinical comparison of alendronate (Fosamax) and denosumab (Prolia) for osteoporosis, with evidence-based guidance on when and how to switch between these two therapies.
A clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) covering efficacy data, pricing, insurance coverage, generic availability, and practical access considerations for osteoporosis treatment.
Fosamax vs Reclast: Fosamax's main side effects are GI (reflux, esophageal irritation); Reclast's is a flu-like reaction after infusion, gone in 72 hours.
Clinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including when and how to switch between these two bone-loss therapies safely.
Clinical guide to switching between Praluent (alirocumab) and Leqvio (inclisiran), comparing LDL-C reduction, cardiovascular outcomes data, dosing schedules, and practical transition protocols.
Evidence-based comparison of atorvastatin (Lipitor) and alirocumab (Praluent) for LDL-C lowering and cardiovascular risk reduction, with trial data from ASCOT-LLA and ODYSSEY OUTCOMES.
Both generics run $4 to $15 a month and sit on Tier 1 of most formularies. Often prescribed together, not as alternatives, for cardiometabolic risk.
A clinical comparison of atorvastatin (Lipitor) and evolocumab (Repatha) covering cost, insurance access, efficacy data from ASCOT-LLA and FOURIER, and practical prescribing guidance.
Compare the side-effect profiles of Lipitor (atorvastatin) and Repatha (evolocumab) across muscle symptoms, liver effects, injection-site reactions, and cardiovascular outcomes from ASCOT-LLA and FOURIER trial data.
Generic atorvastatin costs $4-15/month and cuts LDL 36-50%; ezetimibe runs $9-30/month for 18-25%. See when Zetia gets added to a statin.
Evidence-based comparison of Lipitor (atorvastatin) and Zetia (ezetimibe), including when and how to switch between them, trial data from ASCOT-LLA and IMPROVE-IT, and clinical guidance for cardiometabolic patients.
Yes, Leqvio is typically added to maximally tolerated statins like atorvastatin when LDL-C goals aren't met. Compare costs, dosing, and prior authorization needs.